Product image of Libtayo (Cemiplimab) supplied by GNH India

Libtayo

Active Ingredient:
Cemiplimab
Origin:
EU

Libtayo (Cemiplimab)

Cemiplimab, the active ingredient in Libtayo, is a monoclonal antibody presented as a solution for infusion for intravenous use. It is indicated for the treatment of cutaneous squamous cell carcinoma, advanced basal cell carcinoma, and non‑small cell lung cancer in adult patients.

GNH India supplies Libtayo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Customers receive regulatory documentation and support for import clearance in multiple regions.

Manufacturer / TM Owner

Regeneron Ireland D.A.C.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Libtayo (cemiplimab) is a PD‑1 inhibitor used in oncology to target specific skin cancers and lung cancer.

  • Cutaneous squamous cell carcinoma: improves disease control in patients with locally advanced or metastatic disease.
  • Advanced basal cell carcinoma: provides therapeutic benefit in adults with locally advanced disease not amenable to surgery or radiation.
  • Non‑small cell lung cancer: used for treatment of metastatic disease in patients whose tumors express PD‑L1.

How It Works

  • Cemiplimab is a fully human IgG4 monoclonal antibody that binds with high affinity to the programmed death‑1 (PD‑1) receptor on activated T lymphocytes. By blocking the interaction of PD‑1 with its ligands PD‑L1 and PD‑L2, the drug releases the inhibitory checkpoint, restoring T‑cell mediated immune surveillance and enabling the immune system to recognize and destroy tumor cells.

Side Effects

Cemiplimab may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Fatigue: feeling of tiredness that may affect daily activities.
  • Rash: skin redness or irritation.
  • Pruritus: itching of the skin.
  • Diarrhea: loose or frequent stools.
  • Nausea: sensation of unease in the stomach.
  • Infusion‑related reactions: chills, fever, or flushing during administration.

Serious or Rare Side Effects

  • Pneumonitis: inflammation of lung tissue that can impair breathing.
  • Colitis: severe inflammation of the colon causing abdominal pain and diarrhea.
  • Hepatitis: liver inflammation that may elevate liver enzymes.
  • Endocrinopathies (e.g., hypothyroidism): disruption of hormone production.
  • Severe skin reactions (Stevens‑Johnson syndrome): extensive skin detachment.
  • Myocarditis: inflammation of the heart muscle that can affect cardiac function.

Precautions & Warnings

When using Libtayo, clinicians should observe several precautionary measures to minimize risk.

  • Monitor for immune‑related adverse events: assess organ function regularly.
  • Screen for hepatitis B/C and HIV before initiation.
  • Avoid live vaccines during treatment.
  • Use caution in patients with pre‑existing autoimmune disease.
  • Pregnancy and lactation: safety not established; consider risks vs benefits.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Cemiplimab can interact with other therapies that affect the immune system or share overlapping toxicities.

Major Interactions (Avoid)

  • Concurrent use of other immune checkpoint inhibitors: increased risk of severe immune‑related toxicity.
  • Strong immunosuppressants (e.g., high‑dose steroids): may reduce efficacy.

Moderate Interactions (Monitor Closely)

  • Live vaccines: risk of infection due to immune modulation.
  • Organ transplantation: heightened risk of graft rejection.
  • Concurrent chemotherapy with overlapping toxicity: monitor organ function and blood counts closely.

Frequently Asked Questions

Libtayo (cemiplimab) is approved for the treatment of cutaneous squamous cell carcinoma, advanced basal cell carcinoma, and metastatic non‑small cell lung cancer in adult patients whose tumors express the PD‑L1 protein.

Cemiplimab is a monoclonal antibody that binds to the PD‑1 receptor on T cells, blocking its interaction with PD‑L1 and PD‑L2. This interruption lifts the immune checkpoint, reactivating T‑cell activity against cancer cells.

The dosing regimen for Libtayo is determined by the prescribing oncologist based on the specific indication, patient characteristics, and clinical guidelines. The prescriber sets the dose and infusion schedule.

Safety data for cemiplimab in pregnancy and lactation are limited. It is classified as unknown, and the potential risks to the fetus or infant should be weighed against the therapeutic benefits. Consultation with a specialist is advised.

To request Libtayo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Libtayo (cemiplimab) shares the same PD‑1 target as other agents such as pembrolizumab and nivolumab, but differences exist in approved indications, dosing intervals, and clinical trial data. Choice of therapy depends on the specific cancer type, regulatory approvals, and physician judgment.

Libtayo should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain product integrity.

Libtayo is supplied as a sterile solution for infusion. It is administered intravenously by a qualified healthcare professional, typically over a period of 30 to 60 minutes, according to the dosing schedule prescribed by the treating physician.

Serious risks include immune‑mediated adverse events such as pneumonitis, colitis, hepatitis, endocrinopathies, severe skin reactions (e.g., Stevens‑Johnson syndrome), and myocarditis. Prompt recognition and management of these events are essential.

Libtayo is contraindicated in patients with known hypersensitivity to cemiplimab or any of its excipients. Caution is advised for individuals with active autoimmune diseases, uncontrolled infections, or those receiving live vaccines.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cemiplimab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT